Taysha Gene Therapies, Inc.
For the period ended Sep 30, 2025. Filed Nov 4, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 4, 2025
TSHA$4.37+0.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Other Comprehensive Loss
Condensed Consolidated Statements of Comprehensive Loss
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Net loss | $(32,733) | $(25,524) | $(81,144) | $(70,513) |
| Other comprehensive income (loss): | ||||
| Change in fair value of term loan attributable to instrument specific credit risk | (444) | (4,733) | 2,888 | (2,328) |
| Comprehensive loss | $(33,177) | $(30,257) | $(78,256) | $(72,841) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.